Axona® is a new, prescription dietary supplement (non-drug therapy) designed to support cognition and memory in individuals with Alzheimer's.
Axona is not a replacement for drug therapies that target the chemicals that brain cells need to function, instead, Axona addresses another factor influencing reduced cognition—diminished cerebral glucose metabolism (DCGM).
To function properly, the brain needs too consume a lot of fuel, in the form of a constant supply of glucose (a kind of sugar). When glucose levels are too low, brain cells do not function properly and memory and other cognitive processes are affected.
Research has shown that Alzheimer's interferes with the brain's ability to process and use glucose. This is called diminished cerebral glucose metabolism (DCGM).
However, when glucose levels are too low, the body produces a back-up source of nutrition for the brain know as ketone bodies. Ketone bodies are naturally produced by the liver.
Axona contains fatty acids called medium-chain triglycerides (MCTs), which the body converts into ketone bodies to help support cognition in patients with mild-to-moderate Alzheimer's disease.
Clinical studies have shown that raised ketone body levels can enhance memory and cognition in some people with mild to moderate Alzheimer’s disease.
The John Douglas French Alzheimer's Foundation is funding a study at UCLA examining the cerebral metabolic effects of AC-1202 (Axona®) treatment in mild-to-moderate Alzheimer’s disease (AD), using positron emission tomography (PET). Subjects in the study include both carriers and non-carriers of the APOE4 gene.
The John Douglas French Alzheimer's Foundation also funded an initial study of ketone ester in Alzheimer's disease in mice, conducted by Dr. Richard Veech and Dr Yoshihiro Kashiwaya at the NIH. The study found that feeding the ketone ester to mice (1) decreased amyloid accumulation in brain, (2) decreased phosphorylated tau and (3) improved cognitive performance in the mice.